Rocket Pharmaceuticals shares plummeted 60% Tuesday after the firm said it halted a study of a gene-therapy drug for Danon ...

The U.S. FDA has paused Rocket Pharmaceuticals' mid-stage gene therapy trial after a patient died from serious complications, ...

The U.S. FDA has paused a mid-stage gene therapy trial by Rocket Pharmaceuticals after a patient suffered serious ...

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy ...

Fintel reports that on May 28, 2025, Leerink Partners downgraded their outlook for Rocket Pharmaceuticals (NasdaqGM:RCKT) ...

Barclays analysts downgraded CoreWeave (CRWV) to Equal Weight, raising valuation concerns. This is CoreWeave's first ...

Rocket Pharmaceuticals (RCKT) stock faces a 62% stock drop after FDA's hold on the company's Phase 2 gene therapy trial for ...

Jefferies analyst Andrew Tsai downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to ...

FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...

Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt ...

The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...

The FDA ordered a clinical hold on Rocket Pharmaceuticals' Danon disease trial after the adverse event was first disclosed.